NF2 tumor suppressor gene inactivation along with mutations in CDKN2A/B, and chromatin modulators BAP1, SETD2, and SMARCB1 has been described as driving GA in high-grade/progressive meningioma, and MM similarly to NF2mut RCC.36-38 All these are highly aggressive tumors refractory to conventional therapies. This evidence concerns the gene CDKN2A and renal cell carcinoma.